Genmab A/S (GMAB), a Danish biotechnology firm, announced on Tuesday that the first-quarter sales of Darzalex, Daratumumab, have totaled $2.692 billion, as updated by Johnson & Johnson (JNJ).
Net trade sales were $1.464 billion in the U.S. and $1.228 billion in the rest of the world.
Genmab is entitled to receive royalties on the sales of Darzalex, both the intravenous and SC products, under the exclusive worldwide license to Janssen, a subsidiary of Johnson & Johnson, to develop, make, and commercialize Daratumumab.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.